Stem cell transplantation for light chain amyloidosis: Decreased early mortality over time
Journal of Clinical Oncology Mar 26, 2018
Sidiqi MH, et al. - Herein, researchers report 20 years of experience with autologous stem-cell transplantation (ASCT) for immunoglobulin light chain (AL) amyloidosis at the Mayo Clinic Rochester. For AL amyloidosis, high efficacy of ASCT was documented, with improved survival and markedly reduced treatment-related mortality in eligible patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
